📞 
— free, 24/7
— free, 24/7 — free, 24/7| Dosage | Package | Price per Dose | Price | |
|---|---|---|---|---|
| 5mg | 180 pills | £2.28 | £482.47 £410.10 Best Price | |
| 5mg | 120 pills | £2.38 | £336.74 £286.23 | |
| 5mg | 90 pills | £2.56 | £270.62 £230.02 | |
| 5mg | 60 pills | £2.71 | £191.02 £162.37 | |
| 5mg | 30 pills | £3.33 | £117.55 £99.91 | |
| 10mg | 180 pills | £3.19 | £674.72 £573.51 Popular | |
| 10mg | 120 pills | £3.50 | £493.49 £419.46 | |
| 10mg | 90 pills | £3.61 | £382.05 £324.74 | |
| 10mg | 60 pills | £3.66 | £258.37 £219.61 | |
| 10mg | 30 pills | £4.06 | £143.26 £121.77 |
Vesicare (solifenacin) is a prescription medicine in the antimuscarinic class used to treat symptoms of an overactive bladder, such as sudden urges to urinate, frequent urination, and urge incontinence. It works by reducing involuntary bladder contractions to help improve daily bladder control.
Solifenacin is typically taken once daily and is prescribed after a clinician assesses symptom severity, impact on quality of life, and potential interaction with other medicines. The choice to use Vesicare depends on a patient’s medical history, concurrent conditions, and tolerance of similar medicines.
In the United Kingdom, Vesicare may require a prescription depending on local rules and the patient’s healthcare plan. Your clinician will tailor therapy to your needs, balancing symptom relief with possible side effects and safety considerations.
Vesicare is primarily indicated for adults with overactive bladder symptoms that affect daily living. It can reduce urinary urgency, frequency, and urge incontinence, helping people regain daytime control and sleep quality.
Doctors consider Vesicare alongside other bladder medicines when forming a treatment plan. Alternatives include other antimuscarinics and non-antimuscarinic agents. The choice may hinge on how a patient tolerates side effects like dry mouth, constipation, or blurred vision, as well as other health factors.
Patient-specific factors such as age, kidney or liver function, existing glaucoma, and risk of urinary retention influence the selection. If Vesicare is not well tolerated or ineffective, a clinician may switch to a different agent or combine with non-pharmacological strategies, such as bladder training or pelvic floor exercises, under supervision. Always discuss aims, expectations, and safety with a clinician or pharmacist before changing therapy.
Solifenacin is a member of the antimuscarinic family, but it has a distinct receptor profile that can influence both efficacy and tolerability. Compared with some older antimuscarinics, solifenacin is designed to be more selective for receptors in the bladder, which may translate to fewer or milder side effects for some people.
Compared with a newer non-antimuscarinic option, Vesicare targets bladder muscle activity through a different mechanism. This can offer symptom relief for patients who respond differently to various medicines. The overall effect, duration of action, and side effect pattern vary between medicines, so a clinician may try one option and adjust based on response and tolerability.
In practice, Vesicare may be preferred for people who need daily symptom control and who can tolerate possible dry mouth or constipation. For others, a beta-3 agonist or another bladder-directed medicine might be more suitable, particularly if antimuscarinic side effects are concerning. Always rely on a clinician’s assessment when weighing these choices, and report any troublesome symptoms promptly.
| Name | Primary use | Typical onset | Key advantage |
|---|---|---|---|
| Vesicare (solifenacin) | Overactive bladder symptoms (urgency, frequency, urge incontinence) | Relief may begin within days to weeks; full effect over several weeks | Targeted bladder relaxation with a balance of efficacy and tolerability for many patients |
| Detrol (tolterodine) | Overactive bladder symptoms | Days to weeks | Flexible dosing options; may be better tolerated for some individuals |
| Ditropan (oxybutynin) | Overactive bladder symptoms | Days to weeks | Often effective; can be economical, though more dry mouth and constipation are common |
| Myrbetriq (mirabegron) | Overactive bladder symptoms | Days to weeks | Less likely to cause dry mouth; acts through a different mechanism (beta-3 agonist) |
In practice, the choice between Vesicare and alternatives reflects how well the medicine controls symptoms and how well the person tolerates side effects. A clinician may propose a short trial of a different agent if side effects are bothersome or if symptom control remains suboptimal. Discuss preferences and concerns openly to support a shared decision.
Take Vesicare exactly as prescribed by a clinician. The usual approach is a once-daily dose, taken at roughly the same time each day to help with consistency and adherence.
Swallow the tablet whole with water. Do not crush or chew the tablet unless a pharmacist specifically advises otherwise. Vesicare can be taken with or without food, depending on tolerance and liver function considerations.
If you miss a dose, resume your regular schedule as soon as you remember unless it is almost time for the next dose. Do not double up to make up for a missed dose. If you are unsure how to proceed, contact a pharmacist or clinician for guidance and do not adjust the dose yourself.
Store Vesicare at room temperature, away from moisture and heat. Keep all medicines out of reach of children. If you have trouble opening childproof packaging, ask a pharmacist for assistance. If a suspected overdose occurs, seek urgent medical help immediately and contact a healthcare professional.
Common side effects reflect the antimuscarinic action on various parts of the body. Many people tolerate Vesicare well, but some may experience symptoms that require attention.
Common side effects include dry mouth, constipation, blurred vision, and possibly a warm flush or upset stomach. Some individuals may notice urinary retention, especially if they have pre-existing bladder outlet issues or other risk factors.
Seek medical help if you notice signs of a serious reaction, such as severe allergic symptoms (rash, swelling of the face or throat, severe dizziness), chest pain, fainting, severe eye pain with red eyes, or if you have a marked change in vision, confusion, or swelling of the ankles or legs. If you are pregnant or planning pregnancy, discuss risks with a clinician, as some medicines may affect pregnancy or development. In case of liver or kidney disease, inform the clinician, as dose adjustments may be considered in consultation with a healthcare professional.
Vesicare interacts with other medicines that affect the bladder or cause antimuscarinic effects. Combining Vesicare with multiple antimuscarinic medicines can increase the risk of side effects such as dry mouth, constipation, or cognitive effects, particularly in older adults.
Some medicines can alter the way Vesicare is processed by the body (for example, certain enzyme inhibitors or inducers). In these cases, a clinician might adjust the treatment plan or monitor for changes in effect or side effects. Always inform your clinician about all medicines you take, including over-the-counter products and supplements.
Infection treatments, antidepressants, and certain heart or blood pressure medicines can interact in ways that affect the bladder or overall hydration balance. If you notice new or worsening symptoms after starting Vesicare, contact a healthcare professional for a safety review.
Older adults may experience a higher likelihood of dry mouth, confusion, or dizziness with antimuscarinic medicines. A clinician will assess benefits and risks carefully in this group and monitor for cognitive or balance changes.
People with glaucoma, especially narrow-angle glaucoma, or with a history of urinary retention should discuss the suitability of Vesicare with their clinician. Kidney or liver impairment can influence drug levels and require monitoring or dose considerations.
Pregnancy and breastfeeding require careful consideration. If pregnancy occurs during Vesicare treatment, seek medical advice promptly. Do not stop or start therapy without professional guidance.
Yes. Switching is common when tolerability becomes an issue. A clinician can help choose an alternative with a different side-effect profile and guide a gradual transition to minimize discomfort. Do not stop the medicine without professional advice.
No. Effectiveness and tolerability vary between individuals. Some patients respond better to one medicine while others experience fewer side effects with a different agent. The best choice balances symptom relief with quality of life and safety considerations.
If you miss a dose, take it as soon as you remember unless it is close to the time for your next dose. Do not double up to catch up. If you are unsure, contact a pharmacist or clinician for guidance.
Generic versions of solifenacin may exist depending on local regulations. Generics are required to meet the same quality and safety standards as brand medicines. If you have concerns about switching between brand and generic, discuss it with a pharmacist or clinician.
The choice depends on symptom pattern and side-effect tolerance. Solifenacin’s receptor selectivity can yield a different side-effect profile for some people, and a clinician may prefer it if previous antimuscarinics caused bothersome dryness or constipation. Individual response is key.
Many people take Vesicare with other common medicines, but interactions are possible. A clinician or pharmacist will review your full list of medications to assess safety. Report any new symptoms after starting Vesicare and seek advice promptly.
Discontinuation should be discussed with a clinician. Some people stop therapy once they have symptom relief, but stopping suddenly can lead to a return of symptoms. A healthcare professional can guide a safe plan if you wish to stop or reduce the dose.
Vesicare may be chosen for some patients because its side-effect profile differs from other antimuscarinics. However, individual tolerance varies, and a clinician may consider a non-antimuscarinic option if dry mouth or other bothersome effects are likely. Personal discussion with a clinician is essential.
For official information, consult the patient leaflet provided with the medicine and speak with a pharmacist or doctor. NHS information services and the UK Medicines and Healthcare products Regulatory Agency (MHRA) offer guidance on overactive bladder and relevant treatments, though they should not replace personalized medical advice.
Your pharmacist can explain possible interactions with current medicines, provide tips to manage side effects, and help with practical aspects of taking Vesicare. If symptoms persist or worsen, arrange a review with a clinician to consider alternative strategies or a different medicine.
If you experience severe or sudden symptoms such as chest pain, severe allergic reactions, or signs of urinary retention, seek urgent medical help. Ongoing monitoring and communication with a healthcare professional are important to safe and effective management of bladder symptoms.
14–21 days. Free from £149.98 .
5–9 days. £22.50
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
